Biotech · Private company
Beijing InnoCare Pharma Tech Co., Ltd.
Track this companyFree. Adds Beijing InnoCare Pharma Tech Co., Ltd. to your Dealase workspace and tells you when its record changes.
Clinical trials53 recruiting or active
Pipeline programs6From trials and the company's site
Disclosed deals0None found yet
Cash runwayNot availablePrivate: no SEC financials
Pipeline6
- Drug ICP-192Phase 2 · Advanced Solid TumorsClinicalTrials.gov · fetched Nov 12, 2026
- ICP-322Phase 2 · Prurigo Nodularis (PN)ClinicalTrials.gov · fetched Nov 12, 2026
- orelabrutinibPhase 2 · Relapsing Remitting Multiple SclerosisClinicalTrials.gov · fetched Nov 12, 2026
- Orelabrutinib (ICP-022)Phase 2 · Part 1：r/r B-cell MalignanciesClinicalTrials.gov · fetched Nov 12, 2026
- AzacitidinePhase 1 · Acute Myelogenous LeukemiaClinicalTrials.gov · fetched Nov 12, 2026
- ICP-248Phase 1 · Acute Myelogenous LeukemiaClinicalTrials.gov · fetched Nov 12, 2026
Clinical trials5
- Study of the Efficacy and Safety of ICP-332 in Participants With Prurigo NodularisPHASE2 · RECRUITING · started Nov 27, 2025ClinicalTrials.gov NCT07236099 · fetched Nov 12, 2026
- ICP-248 in Combination With Azacitidine for the Treatment in Patients With Myeloid MalignanciesPHASE1 · RECRUITING · started Dec 18, 2024ClinicalTrials.gov NCT06656494 · fetched Nov 12, 2026
- A Phase 2 Study of Orelabrutinib in Patients With Relapsing-Remitting Multiple SclerosisPHASE2 · UNKNOWN · started Mar 1, 2021ClinicalTrials.gov NCT04711148 · fetched Nov 12, 2026
- A Study of ICP-192 in Patients With Advanced Solid TumorsPHASE1_PHASE2 · UNKNOWN · started Feb 1, 2021ClinicalTrials.gov NCT04565275 · fetched Nov 12, 2026
- A Study of Tyrosine Kinase Inhibitor Orelabrutinib (ICP-022) in Patients With r/r B-Cell MalignanciesPHASE1_PHASE2 · ACTIVE_NOT_RECRUITING · started Nov 18, 2019ClinicalTrials.gov NCT04014205 · fetched Nov 12, 2026